Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.
News|Videos|February 25, 2026
Final Analysis of the Randomized Phase 2 ROSEWOOD Study of Zanubrutinib + Obinutuzumab vs Obinutuzumab Monotherapy in Patients With Relapsed/Refractory Follicular Lymphoma
Author(s)Judith Trotman, MD
ROSEWOOD rapid readout: zanubrutinib plus obinutuzumab boosts durable responses and progression-free survival in relapsed follicular lymphoma, with manageable long-term safety.
Advertisement
This media program features an expert-led presentation reviewing the final analysis of the randomized Phase 2 ROSEWOOD study evaluating zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. The program highlights key efficacy outcomes, durability of response, and safety findings based on extended follow-up, providing clinically relevant insights to inform treatment decision-making in heavily pretreated patients.
Advertisement
Related to this article
Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5